SCHEMBL3385318

SCHEMBL3385318

COCCn1/c(=N/C(=O)c2ccc3ccccc3c2)sc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.55
TP53 P04637 2/20 0.55
HPGD P15428 7/20 0.55
KDM4E B2RXH2 10/20 0.54
ALDH1A1 P00352 9/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
NPSR1 Q6W5P4 3/20 0.54
GAA P10253 2/20 0.54
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
POLB P06746 3/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
MAPT P10636 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
CNR1 P21554 3/20 0.51
CNR2 P34972 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385322 1.00 RXFP1 (0.55) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3384510 0.85 KDM4E (0.56) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3384512 0.85 KDM4E (0.56) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3385143 0.85 ALDH1A1 (0.61) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3385063 0.85 RXFP1 (0.53) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3385072 0.85 RXFP1 (0.53) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3385139 0.85 ALDH1A1 (0.61) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3383574 0.84 CNR1 (0.55) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3383572 0.84 CNR1 (0.55) RXFP1TP53HPGDKDM4EALDH1A1
SCHEMBL3385166 0.84 PIM1 (0.55) RXFP1TP53HPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841334-B2 Compounds as cannabinoid receptor ligands and uses thereof ABBVIE INC. (US) 2014-09-23 US disclosed
US-8546583-B2 Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide ABBVIE INC. (US) 2013-10-01 US disclosed
EP-2222165-B1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC (US) 2013-07-31 EP disclosed
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-04-15 US disclosed
US-20080058335-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC. 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 RXFP1 10/4885TP53 3805/4885HPGD 2262/4885
US-20080058335-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 RXFP1 6/4885TP53 4195/4885HPGD 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.